FibroGen Stock News

LOS ANGELES--(BUSINESS WIRE)---- $FGEN #investors--The Law Offices of Frank R. Cruz Announces Investigation of FibroGen Inc. (FGEN) on Behalf of Investors

SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the Company late today it has tentatively sched

Boston, Massachusetts--(Newsfile Corp. - April 6, 2021) - Block & Leviton is investigating whether FibroGen, Inc. (NASDAQ: FGEN) committed violations of securities fraud, and investors who have lost m

FibroGen Inc. FGEN shares fell in the extended session Tuesday after the biotech drug maker said an analysis of data for its anemia drug revealed inconsistencies in how some safety data was classified

Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat

NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to c

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN). Such investors are a

NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN).  Such investors are advised to c

SAN FRANCISCO, March 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS-2, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN). Such investors are a

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to

The stock price of FibroGen, a biopharmaceutical company focused on therapeutics in immunology and oncology, has seen a large 36% drop over the last ten trading days, while it's down 32% over the last

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN). Such investors are ad

FibroGen suffered a setback after U.S. regulators requested an additional meeting before reviewing the company's anemia treatment. In response, FGEN stock crashed on Tuesday.

FibroGen's (FGEN) CEO Enrique Conterno on Q4 2020 Results - Earnings Call Transcript